A PHASE Ib/II, OPEN LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION C

Protocol: 
AAAR4882
Phase: 
I/II

A PHASE Ib/II, OPEN LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION C

Are you Eligible? (Inclusion Criteria)

1) Age ≥ 18 years at the time of signing Informed Consent Form
2) ECOG Performance Status of 0 or 1 (patient’s level of functioning in terms of their ability to care for themself, daily activity, and physical ability (walking, working, etc.))
3) Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma of gastric or gastroesophageal junction
4) Life expectancy ≥ 3 months, as determined by the investigator

Specialty Area(s)

Immunotherapy

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States